Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer: any role in clinical practice?

Francesco Soria, David D'Andrea, Kamal Pohar, Shahrokh F. Shariat, Yair Lotan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: To summarize the current knowledge about the clinical role of novel urinary markers in bladder cancer (BCa) management, from diagnosis to follow-up, from prognosis of oncological outcomes to response to intravesical therapy. RECENT FINDINGS: Urinary markers have been developed to overcome the limitations of the current available tools for the diagnosis and surveillance of BCa patients. However, to date, because of their limited performances, urinary markers are not generally used in clinical practice. For a marker to be of clinical benefit, it needs to be better, easier, faster and cheaper. The differential requirements for a marker's diagnostic performances depend on goals for clinical utility. Their most promising role seems to be in settings such as in case of equivocal cystoscopy/cytology during follow-up of nonmuscle invasive tumors. Newer markers are available or in development using panels of markers of RNA expression or methylation. SUMMARY: To date, there are multiple urine markers that have improved sensitivity over cytology but there is lack of validation of clinical utility. Some of the recently developed markers aim to change the paradigm of BCa follow-up by replacing or reducing the need of invasive investigations. Further prospective validations are needed to confirm these findings.

Original languageEnglish (US)
Pages (from-to)577-583
Number of pages7
JournalCurrent opinion in urology
Volume28
Issue number6
DOIs
StatePublished - Nov 1 2018

Fingerprint

Urinary Bladder Neoplasms
Cell Biology
Cystoscopy
Methylation
Urine
RNA
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer : any role in clinical practice? / Soria, Francesco; D'Andrea, David; Pohar, Kamal; Shariat, Shahrokh F.; Lotan, Yair.

In: Current opinion in urology, Vol. 28, No. 6, 01.11.2018, p. 577-583.

Research output: Contribution to journalArticle

Soria, Francesco ; D'Andrea, David ; Pohar, Kamal ; Shariat, Shahrokh F. ; Lotan, Yair. / Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer : any role in clinical practice?. In: Current opinion in urology. 2018 ; Vol. 28, No. 6. pp. 577-583.
@article{35f871563b254f3eb64b76358cf7e341,
title = "Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer: any role in clinical practice?",
abstract = "PURPOSE OF REVIEW: To summarize the current knowledge about the clinical role of novel urinary markers in bladder cancer (BCa) management, from diagnosis to follow-up, from prognosis of oncological outcomes to response to intravesical therapy. RECENT FINDINGS: Urinary markers have been developed to overcome the limitations of the current available tools for the diagnosis and surveillance of BCa patients. However, to date, because of their limited performances, urinary markers are not generally used in clinical practice. For a marker to be of clinical benefit, it needs to be better, easier, faster and cheaper. The differential requirements for a marker's diagnostic performances depend on goals for clinical utility. Their most promising role seems to be in settings such as in case of equivocal cystoscopy/cytology during follow-up of nonmuscle invasive tumors. Newer markers are available or in development using panels of markers of RNA expression or methylation. SUMMARY: To date, there are multiple urine markers that have improved sensitivity over cytology but there is lack of validation of clinical utility. Some of the recently developed markers aim to change the paradigm of BCa follow-up by replacing or reducing the need of invasive investigations. Further prospective validations are needed to confirm these findings.",
author = "Francesco Soria and David D'Andrea and Kamal Pohar and Shariat, {Shahrokh F.} and Yair Lotan",
year = "2018",
month = "11",
day = "1",
doi = "10.1097/MOU.0000000000000545",
language = "English (US)",
volume = "28",
pages = "577--583",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer

T2 - any role in clinical practice?

AU - Soria, Francesco

AU - D'Andrea, David

AU - Pohar, Kamal

AU - Shariat, Shahrokh F.

AU - Lotan, Yair

PY - 2018/11/1

Y1 - 2018/11/1

N2 - PURPOSE OF REVIEW: To summarize the current knowledge about the clinical role of novel urinary markers in bladder cancer (BCa) management, from diagnosis to follow-up, from prognosis of oncological outcomes to response to intravesical therapy. RECENT FINDINGS: Urinary markers have been developed to overcome the limitations of the current available tools for the diagnosis and surveillance of BCa patients. However, to date, because of their limited performances, urinary markers are not generally used in clinical practice. For a marker to be of clinical benefit, it needs to be better, easier, faster and cheaper. The differential requirements for a marker's diagnostic performances depend on goals for clinical utility. Their most promising role seems to be in settings such as in case of equivocal cystoscopy/cytology during follow-up of nonmuscle invasive tumors. Newer markers are available or in development using panels of markers of RNA expression or methylation. SUMMARY: To date, there are multiple urine markers that have improved sensitivity over cytology but there is lack of validation of clinical utility. Some of the recently developed markers aim to change the paradigm of BCa follow-up by replacing or reducing the need of invasive investigations. Further prospective validations are needed to confirm these findings.

AB - PURPOSE OF REVIEW: To summarize the current knowledge about the clinical role of novel urinary markers in bladder cancer (BCa) management, from diagnosis to follow-up, from prognosis of oncological outcomes to response to intravesical therapy. RECENT FINDINGS: Urinary markers have been developed to overcome the limitations of the current available tools for the diagnosis and surveillance of BCa patients. However, to date, because of their limited performances, urinary markers are not generally used in clinical practice. For a marker to be of clinical benefit, it needs to be better, easier, faster and cheaper. The differential requirements for a marker's diagnostic performances depend on goals for clinical utility. Their most promising role seems to be in settings such as in case of equivocal cystoscopy/cytology during follow-up of nonmuscle invasive tumors. Newer markers are available or in development using panels of markers of RNA expression or methylation. SUMMARY: To date, there are multiple urine markers that have improved sensitivity over cytology but there is lack of validation of clinical utility. Some of the recently developed markers aim to change the paradigm of BCa follow-up by replacing or reducing the need of invasive investigations. Further prospective validations are needed to confirm these findings.

UR - http://www.scopus.com/inward/record.url?scp=85061536489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061536489&partnerID=8YFLogxK

U2 - 10.1097/MOU.0000000000000545

DO - 10.1097/MOU.0000000000000545

M3 - Article

C2 - 30157039

AN - SCOPUS:85061536489

VL - 28

SP - 577

EP - 583

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 6

ER -